Form 4: Lantern Pharma Insider Selling: Kreis and Related Entities Reduce Stake

Leslie W. Kreis, along with associated entities, reports the sale of Lantern Pharma (LTRN) common stock across multiple transactions on May 23 and 24, 2024.

Summary

• Leslie W. Kreis, a director and 10% owner of Lantern Pharma, along with related entities including Cavu Management, Cavu Advisors, and BP Directors, reported sales of common stock.
• The sales occurred on May 23 and 24, 2024.
• The transactions involved multiple entities including Bios Fund II NT, LP, Bios Fund II QP, LP, and Bios Fund II, LP.
• The shares were sold at weighted average prices of $6.25 on May 23 and $6.33 on May 24.
• The price ranges for the sales on May 23 were $6.08 to $6.49, and on May 24 were $6.15 to $6.64.
• The filing indicates indirect ownership through various investment funds and partnerships.
• The reporting persons disclaim beneficial ownership except to the extent of their pecuniary interest.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to insider selling, which can create uncertainty. However, without knowing the reasons behind the sales, it's difficult to assess the full impact.

Negatives

• The document indicates insider selling, which could be perceived negatively by investors.

Risks

• Continued selling by insiders could put downward pressure on the stock price.
• The reasons for the sales are not disclosed, creating uncertainty for investors.

Industry Context

Insider selling is a common occurrence, but the market often interprets it based on the context of the company's performance and future prospects. It's important to consider this activity in light of Lantern Pharma's overall financial health and strategic direction.

Stakeholder Impact

• Shareholders may react negatively to the insider selling.
• The sales could create downward pressure on the stock price, affecting shareholder value.

Key Dates